[go: up one dir, main page]

PE20080334A1 - Sales del acido 6-metoxi-8-[4-(1-(5-fluoro)-quinolin-8-il-piperidin-4-il)-piperazin-1-il]-quinolina clorhidrico - Google Patents

Sales del acido 6-metoxi-8-[4-(1-(5-fluoro)-quinolin-8-il-piperidin-4-il)-piperazin-1-il]-quinolina clorhidrico

Info

Publication number
PE20080334A1
PE20080334A1 PE2007000722A PE2007000722A PE20080334A1 PE 20080334 A1 PE20080334 A1 PE 20080334A1 PE 2007000722 A PE2007000722 A PE 2007000722A PE 2007000722 A PE2007000722 A PE 2007000722A PE 20080334 A1 PE20080334 A1 PE 20080334A1
Authority
PE
Peru
Prior art keywords
quinolin
piperazin
piperidin
fluoro
methoxy
Prior art date
Application number
PE2007000722A
Other languages
English (en)
Inventor
Jean Schmid
James J Bicksler
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20080334A1 publication Critical patent/PE20080334A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA DE UNA SAL DEL ACIDO MONOCLORHIDRICO DE 6-METOXI-8-[4-(1-(5-FLUORO)-QUINOLIN-8-IL-PIPERIDIN-4-IL)-PIPERAZIN-1-IL]-QUINOLINA QUE TIENE PARAMETROS DE CELULA UNITARIA a=14,4A; b=7,6A; c=28,8A; Y BETA=107,1. SE REFIERE TAMBIEN A UN PROCESO PARA PREPARAR DICHA FORMA CRISTALINA QUE COMPRENDE PRECIPITAR EN UNA SOLUCION ACUOSA, DE PREFERENCIA AGUA Y ETANOL EN UNA RELACION DE APROXIMADAMENTE 1:1 A 1:10. DICHA FORMA CRISTALINA ES INHIBIDOR DE 5HT1A UTIL EN TRASTORNOS RELACIONADOS CON LA COGNICION (DEMENCIA, PARKINSON, ENFERMEDAD DE HUNTINGTON, ALZHEIMER, ENTRE OTROS) O ANSIEDAD (TRASTORNOS OBSESIVO-COMPULSIVO, TRASTORNO DISFORICO PREMENSTRUAL, ANOREXIA NERVIOSA, ENTRE OTROS)
PE2007000722A 2006-06-09 2007-06-08 Sales del acido 6-metoxi-8-[4-(1-(5-fluoro)-quinolin-8-il-piperidin-4-il)-piperazin-1-il]-quinolina clorhidrico PE20080334A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81216806P 2006-06-09 2006-06-09

Publications (1)

Publication Number Publication Date
PE20080334A1 true PE20080334A1 (es) 2008-05-05

Family

ID=38832402

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000722A PE20080334A1 (es) 2006-06-09 2007-06-08 Sales del acido 6-metoxi-8-[4-(1-(5-fluoro)-quinolin-8-il-piperidin-4-il)-piperazin-1-il]-quinolina clorhidrico

Country Status (12)

Country Link
US (1) US20070299083A1 (es)
EP (1) EP2027111A2 (es)
JP (1) JP2009539854A (es)
CN (1) CN101460484A (es)
AR (1) AR061301A1 (es)
AU (1) AU2007258506A1 (es)
BR (1) BRPI0712483A2 (es)
CA (1) CA2653679A1 (es)
MX (1) MX2008015250A (es)
PE (1) PE20080334A1 (es)
TW (1) TW200808741A (es)
WO (1) WO2007146115A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
AR063984A1 (es) * 2006-11-28 2009-03-04 Wyeth Corp Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado
AR065376A1 (es) * 2007-02-16 2009-06-03 Wyeth Corp Formulacion de pastillas de liberacion sostenida de antagonistas y agonistas de piperazina - piperidina del receptor 5 ht1a que tienen disolucion instestinal mejorada
KR101164515B1 (ko) 2009-11-05 2012-07-11 한국 한의학 연구원 인플루엔자 바이러스 유래 질병의 예방 또는 치료용 조성물
WO2018221546A1 (en) 2017-06-01 2018-12-06 Eisai R&D Management Co., Ltd. Pharmaceutical composition comprising pde9 inhibitor
BG67408B1 (bg) 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624954A (en) * 1985-12-20 1986-11-25 American Home Products Corporation 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof, useful for the treatment of cognitive impairments
US4665183A (en) * 1985-12-20 1987-05-12 American Home Products Corp. Process for preparing 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof useful for the treatment of cognitive impairments
US5219857A (en) * 1986-10-16 1993-06-15 American Cyanamid Company Method of treating cognitive and related neural behavioral problems
US4904658A (en) * 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5260331A (en) * 1989-01-02 1993-11-09 John Wyeth & Brother Limited Composition for treating depression with (S- or O-heteroaryl)alkyl amines
US5422355A (en) * 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
MX9201991A (es) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
GB9125615D0 (en) * 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
GB9514901D0 (en) * 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
US6329368B1 (en) * 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
US6313126B1 (en) * 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
IL145209A0 (en) * 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
US6469007B2 (en) * 2000-11-28 2002-10-22 Wyeth Serotonergic agents
BR0116063A (pt) * 2000-12-13 2004-08-03 Wyeth Corp Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
AU2004261606A1 (en) * 2003-07-31 2005-02-10 Wyeth N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-Hydroxytryptamine-6 ligands
WO2005070126A2 (en) * 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
CN1929837A (zh) * 2004-03-02 2007-03-14 惠氏公司 作为神经保护剂和/或神经再生剂的非免疫抑制的亲免素配体
US7247650B2 (en) * 2004-03-02 2007-07-24 Wyeth Macrolides and methods for producing same
JP2008503460A (ja) * 2004-06-16 2008-02-07 ワイス β−セクレターゼのインヒビターとしてのジフェニルイミダゾピリミジンおよびイミダゾールアミン
EP1756087B1 (en) * 2004-06-16 2009-10-07 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof

Also Published As

Publication number Publication date
CA2653679A1 (en) 2007-12-21
MX2008015250A (es) 2008-12-17
CN101460484A (zh) 2009-06-17
TW200808741A (en) 2008-02-16
AR061301A1 (es) 2008-08-20
WO2007146115A3 (en) 2008-04-10
WO2007146115A2 (en) 2007-12-21
JP2009539854A (ja) 2009-11-19
BRPI0712483A2 (pt) 2012-08-28
EP2027111A2 (en) 2009-02-25
US20070299083A1 (en) 2007-12-27
AU2007258506A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
PE20080334A1 (es) Sales del acido 6-metoxi-8-[4-(1-(5-fluoro)-quinolin-8-il-piperidin-4-il)-piperazin-1-il]-quinolina clorhidrico
BR112022010599A2 (pt) Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina
NO20082481L (no) Nye 2-aminoheterosykluser som er nyttige ved behandling av ABETA-relaterte patologier
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
CL2011001992A1 (es) Proceso para producir 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazina que comprende la etapa de precipitar el solvato isopropanol bromhidrato del compuesto a partir de un solvente con mas de 65% (v/v) de isopropanol; proceso de purificacion; y el intermediario solvato isopropanol bromhidrato del compuesto.
GT200600420A (es) Sales novedosas de lisina de derivados de acido 4-((fenoxialquil)tio)-fenoxiacetico
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
BRPI1013482B8 (pt) método para produzir um composto
EA200900857A1 (ru) Замещённые 1-(3-пиридинил)пиразол-4-ил-уксусные кислоты, способ их получения и их применение в качестве гербицидов и регуляторов роста растений
MX2012006562A (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-( 4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas.
CR10088A (es) Compuestos de piperazina con accion herbicida
ES2531190T3 (es) Método para producir un compuesto de 4-oxoquinolina
MA30576B1 (fr) Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique
PE20100261A1 (es) Nuevo procedimiento de sintesis de la agomelatina
PE20040767A1 (es) Derivado hemisulfato de azido citosina cristalino anhidro
AR061299A1 (es) Sales de succionato de 6-metoxi -8- [4- (1-(5- fluor) -quinolin -8-il-piperidin-4-il) -piperazin-1-il] -quinolina y formas cristalinas de las mismas
FR2921565B1 (fr) Procede de recuperation d'acides fluorocarboxyliques
EP1829868A4 (en) PROCESS FOR PREPARING (4,5-DIHYDROXYISOXAZOLE-3-YL) THIOCARBOXAMIDINE SALTS
BR0117054A (pt) Formas cristalinas do ácido 4-[4-[4-hidroxidifenilmetil)-1-piperidinil]-1-hidroxibuti l]-alfa, alfa-dimetilbenzeno acético e seu cloridrato
CL2007000985A1 (es) Uso de un compuesto derivado de piperidinhidroxipropilcarboxamida para tratr osteoartritis y osteoartrosisi; bencenosulfonato de mn-{3-[4-(3,4-diclorofenoxi)piperidin-1-il]-2-hidroxipropil}-2-3dihidro-2-oxo-4-(trifluorometil)-5-tiazolocarboxamida; proceso de preparacion y composiciin farmaceutica.
EP2063710A4 (en) DIFLUORATED PIPERIDINE FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED ACCIDENTS
AR066430A1 (es) Proceso para preparar inhibidores de aromatasa y forma cristalina de exemestano
PE20091028A1 (es) (-) 4-(4-fluorofenil)-7-[({5-[1-hidroxi-1-(trifluorometil)propil]-1,3,4-oxadiazol-2-il}amino)metil]-2h-cromen-2-ona y sus sales como inhibidor de la biosintesis de leucotrienos
CY1112979T1 (el) Διαδικασια για την παρασκευη της ενωσης (s)-1-αλκυλ-2',6'-πιπεκολοξυλιδιδιου
FR2935969B1 (fr) Procede d'obtention de cristaux d'adn par cristallisation en milieu visqueux ; cristaux d'adn et les materiaux energetiques en contenant

Legal Events

Date Code Title Description
FC Refusal